- Home
- MYN vs ERAS Comparison
MYN vs ERAS Comparison
Compare MYN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- ERAS
- Stock Information
- Founded
- MYN 1992
- ERAS 2018
- Country
- MYN United States
- ERAS United States
- Employees
- MYN N/A
- ERAS N/A
- Industry
- MYN Finance Companies
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- ERAS Health Care
- Exchange
- MYN Nasdaq
- ERAS Nasdaq
- Market Cap
- MYN 382.4M
- ERAS 432.6M
- IPO Year
- MYN N/A
- ERAS 2021
- Fundamental
- Price
- MYN $10.00
- ERAS $1.26
- Analyst Decision
- MYN
- ERAS Strong Buy
- Analyst Count
- MYN 0
- ERAS 6
- Target Price
- MYN N/A
- ERAS $4.83
- AVG Volume (30 Days)
- MYN 86.0K
- ERAS 1.8M
- Earning Date
- MYN 01-01-0001
- ERAS 05-07-2025
- Dividend Yield
- MYN 4.12%
- ERAS N/A
- EPS Growth
- MYN N/A
- ERAS N/A
- EPS
- MYN N/A
- ERAS N/A
- Revenue
- MYN N/A
- ERAS N/A
- Revenue This Year
- MYN N/A
- ERAS N/A
- Revenue Next Year
- MYN N/A
- ERAS N/A
- P/E Ratio
- MYN N/A
- ERAS N/A
- Revenue Growth
- MYN N/A
- ERAS N/A
- 52 Week Low
- MYN $8.47
- ERAS $1.04
- 52 Week High
- MYN $10.62
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MYN 47.13
- ERAS 36.09
- Support Level
- MYN $9.80
- ERAS $1.40
- Resistance Level
- MYN $10.17
- ERAS $1.61
- Average True Range (ATR)
- MYN 0.10
- ERAS 0.12
- MACD
- MYN 0.00
- ERAS -0.01
- Stochastic Oscillator
- MYN 52.70
- ERAS 38.60
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.